CHMP recommends approval of Bristol Myers Squibb’s Reblozyl

By vbandhakavi

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Bristol Myers Squibb’s Reblozyl (luspatercept) for adult patients with anemia associated with non‑transfusion-dependent (NTD) beta thalassemia.